These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 9876613)

  • 1. Transdermal delivery of isosorbide 5-mononitrate from a new membrane reservoir and matrix-type patches.
    Arra GS; Arutla S; Krishna DR
    Drug Dev Ind Pharm; 1998 May; 24(5):489-92. PubMed ID: 9876613
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of a membrane-controlled transdermal therapeutic system containing isosorbide dinitrate.
    Ocak F; Ağabeyoğlu I
    Int J Pharm; 1999 Apr; 180(2):177-83. PubMed ID: 10370188
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel transdermal patch incorporating isosorbide dinitrate with bisoprolol: in vitro and in vivo characterization.
    Zhao JH; Fu JH; Wang SM; Su CH; Shan Y; Kong SJ; Wang Y; Lu WL; Zhang H; Zhang S; Li L; Zhang EH; Wang L; Pei QL; Wang JC; Zhang X; Zhang Q
    Int J Pharm; 2007 Jun; 337(1-2):88-101. PubMed ID: 17267147
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of novel immediate-/controlled-release tablets of isosorbide-5-mononitrate (5-ISMN): in vitro-in vivo correlation.
    Li X; Jiang Q; Du L; Li Y; Li M
    Pharmazie; 2014 Feb; 69(2):109-16. PubMed ID: 24640599
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined effect of liposomalization and addition of glycerol on the transdermal delivery of isosorbide 5-nitrate in rat skin.
    Barichello JM; Yamakawa N; Kisyuku M; Handa H; Shibata T; Ishida T; Kiwada H
    Int J Pharm; 2008 Jun; 357(1-2):199-205. PubMed ID: 18343610
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of several electrolyzed waters on the skin permeation of lidocaine, benzoic Acid, and isosorbide mononitrate.
    Kitamura T; Todo H; Sugibayashi K
    Drug Dev Ind Pharm; 2009 Feb; 35(2):145-53. PubMed ID: 19065312
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of monolithic osmotic pump tablet system for isosorbide-5-mononitrate delivery and evaluation of it in vitro and in vivo.
    Duan X; Liu Q; Zhang Y; Bi K; Chen X; Wang Y; Luo G
    Drug Dev Ind Pharm; 2009 Apr; 35(4):499-507. PubMed ID: 18979308
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Membrane permeation-controlled transdermal delivery system design. Influence of controlling membrane and adhesive on skin permeation of isosorbide dinitrate.
    Seki T; Kawaguchi T; Sugibayashi K; Juni K; Morimoto Y
    Chem Pharm Bull (Tokyo); 1990 Mar; 38(3):740-3. PubMed ID: 2347017
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of penetration enhancers on isosorbide dinitrate penetration through rat skin from a transdermal therapeutic system.
    Gabiga H; Cal K; Janicki S
    Int J Pharm; 2000 Apr; 199(1):1-6. PubMed ID: 10794921
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preparation of multi-chamber gastrointestinal diffusion system for isosorbide-5-mononitrate.
    Sawicki W; Janicki S
    Pharmazie; 1992 Jun; 47(6):465-6. PubMed ID: 1409844
    [No Abstract]   [Full Text] [Related]  

  • 11. [Studies on transdermal delivery system of isosorbide dinitrate].
    Ji AM; Jiang XT; Wang XF; Zou HQ
    Yao Xue Xue Bao; 1992; 27(11):858-63. PubMed ID: 1300032
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Determination of isosorbide-5-mononitrate in plasma by GC-ECD and study on its pharmacokinetics in ten volunteers].
    Yang LL; Yuan YS; Zhao FL
    Yao Xue Xue Bao; 1997 Oct; 32(10):773-6. PubMed ID: 11596222
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Electron beam irradiation: a novel technology for the development of transdermal system of isosorbide dinitrate.
    Kotiyan PN; Vavia PR; Bhardwaj YK; Sabarwal S; Majali AB
    Int J Pharm; 2004 Feb; 270(1-2):47-54. PubMed ID: 14726121
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Permeability test for transdermal and local therapeutic patches using Skin PAMPA method.
    Vizserálek G; Berkó S; Tóth G; Balogh R; Budai-Szűcs M; Csányi E; Sinkó B; Takács-Novák K
    Eur J Pharm Sci; 2015 Aug; 76():165-72. PubMed ID: 25957747
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro and in vivo evaluation of novel osmotic pump tablets of isosorbide-5-mononitrate containing polyvinyl pyrrolidone (PVP) for controlled release.
    Li X; Jiang Q; Du L; Wang C; Chi Q
    Pharmazie; 2012 Aug; 67(8):695-700. PubMed ID: 22957434
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics of isosorbide mononitrate.
    Abshagen UW
    Am J Cardiol; 1992 Nov; 70(17):61G-66G. PubMed ID: 1449102
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Absorption of isosorbide-5-mononitrate at specific sites in the gastrointestinal tract.
    Kramer WG
    J Clin Pharmacol; 1994 Dec; 34(12):1218-21. PubMed ID: 7738218
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The plasma concentrations of isosorbide 5-mononitrate (5-ISMN) administered in an extended-release form to patients with acute myocardial infarction.
    McClennen W; Hornestam B; Jonsson UE; Held P
    Br J Clin Pharmacol; 1995 Jun; 39(6):704-8. PubMed ID: 7654494
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potential usefulness of solubility index for prediction of the skin permeation rate of 5-ISMN from pressure-sensitive adhesive tape.
    Sato K; Mitsui N; Hasegawa T; Sugibayashi K; Morimoto Y
    J Control Release; 2001 Jun; 73(2-3):269-77. PubMed ID: 11516504
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A sustained release formulation of isosorbide-5-mononitrate with a rapid onset of action.
    Arthur RM; Mehmel H
    Int J Clin Pract; 1999; 53(3):205-12. PubMed ID: 10665134
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.